Selecta Biosciences appoints Timothy C. Barabe to board
Most recently serving as chief financial officer and executive vice president at Affymetrix Inc., Mr. Barabe has extensive experience in the life sciences industry, having held a broad range of financial and strategic roles.
He served as the chief financial officer and executive vice president at Affymetrix Inc., where he led the company’s financial functions as well as the treasury, investor relations, and information technology departments.
Previously, he served as senior vice president and chief financial officer at Human Genome Sciences.
For more than 20 years, he held senior international executive roles in finance, general management, and strategic planning at Novartis AG, one of the world’s largest pharmaceutical companies.
His roles included chief financial officer of the Sandoz Generics Business Unit, president of the CIBA Vision Corporation Specialty Lens Business Franchise, and group vice president and chief financial officer of CIBA Vision Corporation.
Mr. Barabe has a B.B.A. in Finance from the University of Massachusetts (Amherst) and an M.B.A. from the University of Chicago.
He also serves as a director of several public company boards, including ArQule, Opexa Therapeutics and Vigilant Biosciences. ■
LATEST MOVES FROM Massachusetts
- Haemonetics Corporation appoints Robert E. Abernathy to board
- Tetraphase Pharma appoints Kamalam Unninayar as CFO
- Boston Biomedical appoints Edgar Braendle as vice president
- Analogic Corporation appoints Joseph Whitters to board
- Eleven Biotherapeutics appoints Richard F. Fitzgerald as interim CFO
More inside POST
Act like a manager and you will become one Leadership
New CEOs have 100 days to boost stock prices Leadership